Iterum Therapeutics Plc

Iterum Therapeutics Plc company information, Employees & Contact Information

Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. These products are aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. For more information on Iterum Therapeutics please visit www.iterumtx.com.

Company Details

Employees
20
Founded
-
Address
3 Dublin Landings North Wall Quay, Dublin,ireland 1,ireland
Phone
+353 1 903 8920
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Dublin, Ireland
Looking for a particular Iterum Therapeutics Plc employee's phone or email?

Iterum Therapeutics Plc Questions

News

Iterum Therapeutics Announces U.S. Commercial Launch of ORLYNVAHTM Targeted for Q4 2025 in Partnership with EVERSANA - Quiver Quantitative

Iterum Therapeutics Announces U.S. Commercial Launch of ORLYNVAHTM Targeted for Q4 2025 in Partnership with EVERSANA Quiver Quantitative

Phase 3 data of oral sulopenem for uUTIs published in NEJM Evidence - Urology Times

Phase 3 data of oral sulopenem for uUTIs published in NEJM Evidence Urology Times

Breakthrough UTI Drug ORLYNVAH Set for Q4 2025 Launch: First Oral Penem Antibiotic in US History - Stock Titan

Breakthrough UTI Drug ORLYNVAH Set for Q4 2025 Launch: First Oral Penem Antibiotic in US History Stock Titan

Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth - Yahoo Finance

Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth Yahoo Finance

FDA approves oral sulopenem for uncomplicated urinary tract infection - Urology Times

FDA approves oral sulopenem for uncomplicated urinary tract infection Urology Times

Iterum Therapeutics Grants Share Option to Chief Commercial Officer Christine Coyne as Part of Employment Agreement - Quiver Quantitative

Iterum Therapeutics Grants Share Option to Chief Commercial Officer Christine Coyne as Part of Employment Agreement Quiver Quantitative

Novel Antibiotic Sulopenem Misses Primary End Point in cIAI Trial - Medical Professionals Reference

Novel Antibiotic Sulopenem Misses Primary End Point in cIAI Trial Medical Professionals Reference

Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. - Yahoo Finance

Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. Yahoo Finance

FDA Advisory Committee meets to discuss NDA of oral sulopenem for uUTI - Urology Times

FDA Advisory Committee meets to discuss NDA of oral sulopenem for uUTI Urology Times

Top Iterum Therapeutics Plc Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant